The most widely used imaging modality for the prostate is TRUS; however, there are no clearly defined standards for the clinical approach for each individual biopsy procedure, dealing with continuous technical optimization and in particular the developments in imaging. In this review the current ...
cancer (OR: 1.28, p < 0.001) and specifically for significant prostate cancer (OR: 1.46, p < 0.001) in uni-variate analyses. However, multi-variate analyses using age, PSA, prostate volume, DRE and transrectal ultrasonography outcome, and previous biopsy (yes/no) showed that PSAV was not ...
for analysis. It measures how much prostate-specific antigen you have in your blood. There's no set level to tell doctors whether you have prostate cancer. But the higher the level, the more likely you'll need further tests, such as a biopsy,MRI, or other lab tests to check for ...
Prostate biopsies incur the risk of being false-negative and this risk has not yet been evaluated for 12-core prostate biopsy. We calculated the false-negative rate of 12-core prostate biopsy and determined the patient characteristics which might affect detection rate.We included 90 prostate cancer...
Before the biopsy procedure, the physician measured the ESR using a function embedded in the ultrasound system. After confirming the target lesion with B-mode ultrasound, the physician set the elastography color-coded map to include a sufficient area of the whole prostate concomitant with real-time...
Moreover, because of the heterogeneous and multifocal nature of this disease, the likelihood of missing the lesion during the biopsy is high, with a high morbidity associated with invasive biopsy procedure41. Using our method, cells shed from the prostate into urine could be analysed instead; ...
Background: Transrectal ultrasound guided systematic biopsies of the prostate is a routine procedure to establish a prostate cancer diagnosis. However, the 10-12 prostate core biopsies only sample a relatively small volume of the prostate, and tumour lesions in regions between biopsy cores can be mi...
The time between prostate biopsy and radical prostatectomy does not appear to have a large effect on the risk of disease recurrence, according to researchers at Memorial Sloan-Kettering Cancer Center, New York. The time between prostate biopsy and radical prostatectomy does not appear to have a ...
All patients who were potent before the procedure maintained potency after the procedure. Continence levels were not compromised. Based on multi-core total prostate biopsy at 6 months, 67 % of patients were free of tumor in the targeted area and 50 % were free of disease. The authors ...
Patterns of visits to specialists Patients were evaluated by one of 2832 index urologists who performed the diagnostic biopsy. Including the initial diagnostic procedure and all physician visits in the subsequent 9 months, 4298, 1545, and 1552 unique urologists, radiation oncologists, and medical onco...